Are you speculating when you make that statement? Perhaps B-OM or B-UP is the quickest route to FDA approval for a single indication, suddenly enabling a partnership well before a global ABSSSI trial could conclude and result in approval. The attention that our new President is applying to our pipeline as a whole with the experience that he brings to the table has resulted in some correction to the corporate trajectory with respect to drug development priorities. I think it is worth seeing where this new trajectory is pointing us before everyone starts expressing opinions that are very short of all the knowledge our insider President now possess.